OVCAR-8-Luc Cells
US$ 800,00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
Informações gerais
| Descrição | OVCAR-8-Luc cells are a bioluminescent derivative of the human ovarian adenocarcinoma cell line OVCAR-8, which was originally established from an adult patient with advanced-stage disease. These cells have been genetically engineered to stably express luciferase, an enzyme that catalyzes light emission in the presence of its substrate, enabling highly sensitive, non-invasive monitoring of cellular activity. The parental OVCAR-8 line is characterized by aggressive growth, genomic instability, and features representative of high-grade serous ovarian cancer, making it a widely used model for studying ovarian tumor biology. The incorporation of luciferase allows OVCAR-8-Luc cells to be used in longitudinal in vivo imaging applications, particularly in xenograft and orthotopic tumor models, where tumor burden and metastatic dissemination can be quantitatively tracked over time using bioluminescence imaging. These cells retain key molecular and phenotypic traits of the parental line, including alterations in pathways relevant to ovarian cancer progression such as p53 dysfunction and dysregulated cell cycle control. Consequently, OVCAR-8-Luc cells are well suited for evaluating therapeutic efficacy, tumor growth kinetics, and metastatic behavior, as well as for studying tumor microenvironment interactions in preclinical research. |
|---|---|
| Organismo | Human |
| Tecido | Ovary |
| Doença | Adenocarcinoma |
| Local da metástase | Primary tumor site (ovary) |
| Aplicações | Ovarian cancer research; bioluminescence imaging in xenograft/orthotopic models; in vivo tumor burden tracking; drug efficacy and pharmacodynamics; PARP inhibitor and platinum sensitivity studies; peritoneal metastasis modeling; ovarian cancer immunotherapy evaluation |
| Sinônimos | OVCAR 8, NIH:OVCAR-8, OVCAR8, Ovcar8, OVCAR.8, OVCA8, OVCAR-8/EGFP_LC3 |
Características
| Idade | 64 years |
|---|---|
| Gênero | Female |
| Etnia | Caucasian |
| Morfologia | Epithelial-like |
| Tipo de célula | Epithelial cells |
| Propriedades de crescimento | Adherent |
Dados regulatórios
| Referência | OVCAR-8-Luc (Cytion catalog number 305697) |
|---|---|
| Nível de biossegurança | 1 |
| NCBI_TaxID | 9606 |
| Número de acesso do Cellosaurus | CVCL_2169 |
| Situação em relação aos OGMs | GMO-S1: This human ovarian carcinoma cell line (OVCAR-8-Luc) contains a lentiviral firefly-Luc reporter construct, enabling bioluminescent tracking. The insert is stably integrated. This classification applies only within Germany and may differ elsewhere. |
Dados biomoleculares
| Expressão de proteínas | Luc |
|---|
Manuseio
| Meio de cultura | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Suplementos | Supplement the medium with 10% FBS |
| Reagente de dissociação | Accutase |
| Densidade de semeadura | 1-3 x 104 cells/mL |
| Renovação de fluidos | 2 to 3 times per week |
| Meio de congelamento | As a cryopreservation medium, we use complete growth medium + 10% DMSO for adequate post-thaw viability. |
| Descongelamento e cultura de células |
|
| Atmosfera de incubação | 37°C, 5% CO2, humidified atmosphere. |
| Condições de envio | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Condições de armazenamento | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Controle de Qualidade e Análise Molecular
Certificado de Análise (CoA)
| Número do lote | Tipo de certificado | Data | Número de catálogo |
|---|---|---|---|
| 305697-090326 | Certificado de Análise | 13. Apr. 2026 | 305697 |